Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed.

1. HSV-2 genome recognition by nuclear cGAS instigates IFN-β production and influences inflammasome activation duringFrontiers in immunology · 2026
   Article
2. Inhibition of STING-mediated antiviral innate immunity activation by CD97 via modulation of ER-phagy.Communications biology · 2025
   Article
3. Altered LY6E and TRIM6 expression in PBMCs correlated with HBsAg clearance and response to Peg-IFN-α treatment in HBeAg-negative chronic hepatitis B patients.Virology journal · 2025
   Article
4. Double-stranded RNA orbivirus disrupts the DNA-sensing cGAS-sting axis to prevent type I IFN induction.Cellular and molecular life sciences : CMLS · 2025
   Article
5. An arms race between 5'ppp-RNA virus and its alternative recognition receptor MDA5 in RIG-I-lost teleost fish.eLife · 2024
   Article
6. MAVI1, an endoplasmic reticulum-localized microprotein, suppresses antiviral innate immune response by targeting MAVS on mitochondrion.Science advances · 2023
   Article
7. Mechanism of herpesvirus UL24 protein regulating viral immune escape and virulence.Frontiers in microbiology · 2023
   Review
8. Escape and Over-Activation of Innate Immune Responses by SARS-CoV-2: Two Faces of a Coin.Viruses · 2022
   Review
9. Sequence Analysis ofFrontiers in veterinary science · 2022
   Article
10. Regulation of cGAS/STING signaling and corresponding immune escape strategies of viruses.Frontiers in cellular and infection microbiology · 2022
    Review
11. ADAR Editing in Viruses: An Evolutionary Force to Reckon with.Genome biology and evolution · 2021
    Review
12. The COVID-19 pandemic: an increased risk of rheumatoid arthritis.Future virology · 2021
    Review
13. The Rheumatology Drugs for COVID-19 Management: Which and When?Journal of clinical medicine · 2021
    Review
14. Tick-borne encephalitis virus NS4A ubiquitination antagonizes type I interferon-stimulated STAT1/2 signalling pathway.Emerging microbes & infections · 2020
    Article
15. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2020
    Review
16. Impact of Porcine Arterivirus, Influenza B, and Their Coinfection on Antiviral Response in the Porcine Lung.Pathogens (Basel, Switzerland) · 2020
    Article
17. Evasion of Type I Interferon by SARS-CoV-2.Cell reports · 2020
    Article
18. West Nile Virus Restriction in Mosquito and Human Cells: A Virus under Confinement.Vaccines · 2020
    Review
19. COVID-19 infection and rheumatoid arthritis: Faraway, so close!Autoimmunity reviews · 2020
    Review
20. Human Alveolar and Splenic Macrophage Populations Display a Distinct Transcriptomic Response to Infection WithFrontiers in immunology · 2020
    Article

Corrections and comments

• Erratum for
  A diverse range of gene products are effectors of the type I interferon antiviral response.2011

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.